Martin Babler
CIK 1435618 · President, CEO and Chairman · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.05M
Companies
8
Total Filings
34
Lifetime Open-Market Net
-$3.34M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MPLT | Director | 7,864 | $12.07 | $95.0K | $0 | 1 | 2026-06-25 |
| PRLD | Director | — | $4.68 | — | $0 | 6 | 2026-06-10 |
| ALMS | President, CEO and Chairman | 109,454 | $26.96 | $2.95M | $100.7K | 5 | 2026-01-28 |
| 89bio, Inc. (ETNB) Delisted | Director | — | $14.84 | — | $0 | 3 | 2025-10-30 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 4 | 2023-06-09 |
| Principia Biopharma Inc. (PRNB) Delisted | President, CEO | 0 | — | — | -$3.45M | 6 | 2020-09-28 |
| ZS Pharma, Inc. (ZSPH) Delisted | Director | — | — | — | $0 | 1 | 2015-06-25 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 6 | 2013-06-13 |
Recent Filings · Page 2 of 4
34 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-18 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2024-05-03 | 89bio, Inc. (ETNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-07 | NGNE | Notice (144) | −2,500 | -$98.2K | EDGAR |
| 2023-06-21 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | Neurogene Inc. (NLTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-22 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2022-05-16 | Neurogene Inc. (NLTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-20 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2021-05-13 | Neurogene Inc. (NLTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-09-28 | Principia Biopharma Inc. (PRNB) Delisted | Mixed | −58,557 | -$5.86M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.